Abstract
The NAD(P)H quinone oxidoreductase (NQO1:EC 1.6.99.2) is an important biotransformation enzyme system that is also known to metabolize important novel chemotherapeutic compounds. The gene that codes for this enzyme has recently been found to be polymorphic in humans. Here, we describe the ethnic distribution of the polymorphism and note that this may have implications for anti-tumour drug development and use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kelsey, K., Ross, D., Traver, R. et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76, 852–854 (1997). https://doi.org/10.1038/bjc.1997.474
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.474
This article is cited by
-
Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound
Cell Death & Disease (2021)
-
NQO1 C609T Polymorphism is Associated with Coronary Artery Disease in a Gender-Dependent Manner
Cardiovascular Toxicology (2017)
-
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves
European Journal of Clinical Pharmacology (2015)
-
NQO1 C609T polymorphism is associated with esophageal cancer risk among Chinese: a meta-analysis
Tumor Biology (2014)
-
Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population
Molecular Biology Reports (2013)